Online Webinars

Previous Webinars

Jun 26, 2017

Imaging-based subtypes of pancreatic cancer

The outcomes of pancreatic cancer have seen little improvement over the past three decades. The disease is associated with a poor prognosis and lack of response to chemotherapy and radiation. To date, there are no reliable ways to separate patients into prognostic groups based on the cancer biology, which would...
View Full Event Post
May 10, 2017

Quantitative Immunohistochemistry for Development of Predictive Biomarkers in Oncology Clinical Trials

In oncology studies, biomarkers have been effectively used to measure tumor progression and to evaluate efficacy of therapies. Increasingly they have been utilized to stratify different patient groups and to develop personalized therapeutic strategies. Towards this goal, immunohistochemistry (IHC) has been playing an increasing role to help understand the mechanism...
View Full Event Post
Mar 21, 2017

Evaluation of the tumor microenvironment using image analysis for clinical trials.

The number of clinical trials examining immunotherapy and combination therapies with immunotherapy as a backbone has exceeded 1000 in 2016. While PD-L1 by immunohistochemistry has been successfully employed as a companion diagnostic for several therapies across a handful of indications, PD-L1 is only one potential biomarker for showing predictive response....
View Full Event Post
Dec 6, 2016

Late Breaking Data from the Society for Immunotherapy of Cancer 2016

Immunotherapies have improved patient responses and survival, though not all patients benefit. Effective biomarkers may help improve outcomes. Durvalumab is a human IgG1 monoclonal antibody that inhibits programmed death ligand-1 (PD-L1) binding to programmed death-1 and B7.1/CD80, restoring antitumor immunity. PD-L1 expression on tumor or tumor-infiltrating immune cells measured manually...
View Full Event Post
Oct 18, 2016

Tissue Collection Standards Determine the Future of Precision Medicine

As most compounds target specific cancer pathways, identification of pathways and their potential role as drivers for cancer growths in the individual tumor has become an attractive approach for prediction of drug response. Mutation analysis of cancer relevant genes has become the most widely used approach because DNA is a...
View Full Event Post